Patients with intermittent claudication are less likely to experience pain in their legs when walking if they take the vasodilatory drug naftidrofuryl, according to the findings of a Cochrane Review.
Cochrane researchers studied data from seven clinical trials that compared naftidrofuryl with placebos.
They found that patients who took 200mg of the drug - three times a day for at least three months - had 37% more pain-free walking than those taking a placebo.
In 55% of patients taking naftidrofuryl the condition also improved, compared to only 30% of those on a placebo, the reviewers added.
Lead researcher Tine de Backer, from the Heymans Institiute of Pharmacology in Gent, Belgium, said: ‘It would make sense to give naftidrofuryl alongside recommending lifestyle changes such as stopping smoking, physical exercise and also prescribing anti-platelet drugs and statins.’